Northgate Medical Center, Springfield, MA 01103, United States.
World J Gastroenterol. 2013 Feb 21;19(7):1085-90. doi: 10.3748/wjg.v19.i7.1085.
To evaluate the safety and efficacy of Chlorella in 18 patients chronically infected with hepatitis C virus (HCV) genotype 1.
Eighteen adults with chronic infection by HCV genotype 1 received daily oral supplementation of Chlorella for 12 wk. Changes in the RNA levels of HCV, as well as those of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were evaluated following this treatment period. Paired t tests were conducted to compare the means of the different variables at the beginning and end of the study. Side effects and quality of life aspects were also compared between weeks 0 and 12 of the study period.
A majority 84.61% of the patients had a significant decrease in their ALT levels from week 0 to week 12. Evaluation of side effects showed that Chlorella was well tolerated. Quality of life assessment showed that 76.9 of the participants reported an improvement in their energy levels and 46.1% reported an improvement in their perception of general health. Although 69.23% also showed a decrease in their AST levels, this was not statistically significant. Most patients that exhibited an improvement in their ALT and AST levels also showed a tendency toward a decreased HCV viral load. The HCV RNA levels showed a decrease in 69.23% of the patients, which along with changes in AST/ALT ratios from week 0 to week 12, these results were not statistically significant.
Chlorella supplementation was well tolerated in patients with chronic HCV and associated with a significant decrease in ALT liver enzyme levels.
评估小球藻在 18 例慢性丙型肝炎病毒（HCV）基因型 1 感染者中的安全性和疗效。
18 例慢性 HCV 基因型 1 感染者每日口服小球藻补充剂，疗程 12 周。治疗结束后，评估 HCV RNA 水平以及天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）水平的变化。采用配对 t 检验比较研究前后各变量的均值。还比较了研究期间 0 周和 12 周时的不良反应和生活质量方面。
大多数患者（84.61%）的 ALT 水平从第 0 周降至第 12 周时有显著下降。评估不良反应的结果表明，小球藻的耐受性良好。生活质量评估显示，76.9%的参与者报告其精力水平提高，46.1%的参与者报告其总体健康状况改善。尽管 69.23%的患者 AST 水平也有所下降，但无统计学意义。大多数 ALT 和 AST 水平改善的患者，其 HCV 病毒载量也呈下降趋势。69.23%的患者 HCV RNA 水平下降，AST/ALT 比值在第 0 周至第 12 周之间的变化无统计学意义。
小球藻补充剂在慢性 HCV 患者中耐受良好，与 ALT 肝酶水平的显著下降相关。
